OSE-279 is under clinical development by OSE Immunotherapeutics and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how OSE-279’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OSE-279 overview
OSE-279 is under development for the treatment of niche tumor (solid tumor), lymphomas, sarcomas, hepatocellular carcinoma, anal squamous cell carcinoma, undifferentiated pleomorphic sarcoma, oncocytic thyroid cancer, and alveolar soft part sarcoma. The drug candidate is a bi-specific fusion protein comprising anti-PD1 antibody simultaneously delivering intratumoral cytokines developed based on bi-specific checkpoint inhibitor (BiCKI) platform. It acts by targeting programmed cell death protein 1(PD-1) and interleukin-7 (IL-7). It is administered through intravenous route.
OSE Immunotherapeutics overview
OSE Immunotherapeutics (OSE) is a biotechnology company that discovers and develops immune systems for immuno-oncology and immuno-inflammation. The company products include tedopi, OSE-279, FR104, BI 765063, OSE-230, BiCKI and CLEC-1. Its products treat NSCLC post-ICI, NSCLC combo 2L post-ICI, PDAC combo maintenance, OC mono and combo, solid tumor, lymphoma, kidney transplant, MSS endometrial, MSS CRC, inflammation diseases and immuno-oncology. OSE carries out clinical asset and pre-clinical platforms such as myeloid platform and BiCKI platform. The has collaborations and partnerships with pharmaceutical leaders, clinical organizations and academic laboratories. OSE is headquartered in Nantes, Pays-de-la-Loire, France.
For a complete picture of OSE-279’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
